DE EN Anmelden

In your studies 'Drug Regulator Affairs'

©Volker Lannert / Universität Bonn

Master's thesis


As part of the continuing education Master's degree programme, Master's theses are written on relevant topics in the field of 'Drug Regulatory Affairs' using scientific methods. The topics are highly topical, diverse and the results are both of interest in a scientific context and relevant to many areas of activity in 'Drug Regulatory Affairs'.

Here you will find all Master's theses written since the year 2000, including the title and a summary. In this collection, many Master's theses can also be viewed and downloaded in full text.

Further information on Master's theses (e.g. registration, processing) can be found in our ‘Master's thesis guidelines/Leitfaden für die Anfertigung einer Masterarbeit’ (in German) and in the ‘Information leaflet - Master's thesis’ at

Downloads from A-Z

Do you have any questions or are you interested in the full text of a Master's thesis that is not listed here?
Please feel free to contact me.

Dr. Jasmin Fahnenstich

Dr. Jasmin Fahnenstich

Study programme manager

Phone: +49 (0) 228 - 9268 6806

Send e-mail

Master's thesis

The collection of Master's theses can be searched and sorted by entering keywords.

Year Name Title Full text Summary
2005 Dr. Joachim Gramberg Über die Abgrenzungsproblematik bei Repellents ***
2005 Dr. Markus Hartmann Impact of the new legislative framework within the European Union on non-commercial clinical research and investigator-initiated trials: a cross-European analysis with focus on oncology ***
2005 Dr. Andrea Klüting The Effects of the 12th Amendment to the German Pharmaceuticals Act on Clinical Trials in Academic Institutions and the Pharmaceutical Industry ***
2005 Dr. Daniela Lieder Evaluation and consideration of resistance data on the licensing process of antibiotics ***
2005 Dr. Boris Mey Marketing authorisation of medicinal products used to prevent the toxicity of chemical, biological, radiological or nuclear substances (MA of Anti-CBRN Drugs) ***
2005 Dr. Wolfgang Meyer Preclinical and clinical development of anticancer drugs - regulatory peculiarities
2005 Dr. Rainer Paffenholz Nonclinical assessment of immunotoxicity in the EU, United States, and Japan ***
2005 Dr. Karen Rosenkranz Regulatory strategies for life-cycle management of chemical defined cytostatic drugs with regard to the new pharmaceutical legislation ***
2005 Dr. Sabine Schiemann New aspects in comparability studies of biotechnological products subject to changes in the manufacturing process
2005 Ingrid Schulz Comparison of CMC requirements for Clinical Trials in the US and the European Union ***
2005 Dr. Karin Streso Demarcation of medicinal products and food in the European Union - Focus on food supplements ***
2005 Dr. Michael Sych Structure and implementation of an adequate quality assurance system in a pharmaceutical start-up company ***
2005 Ute Ukelis Replacement of In Vivo ATC Studies by In Vitro Cytotoxicity Methods
2005 Elke Wehres-Losch Die Anmeldung klinischer Prüfungen in Deutschland nach der 12. AMG-Novelle – Erste Erfahrungen und kritische Aspekte aus Sicht der pharmazeutischen Industrie ***
2005 Dr. Bernhard Wenkers Balancing Regulatory and Economic Aspects in the Development of Generics – a Business Case ***
2005 Dr. Arno Wiehe Data protection for the development of known drug substances - Changes with the review of EU legislation ***
2005 Matthias Wilken Empfehlungen zur Erstellung eines Maßnahmeplans unter Anpassung an die aktuellen gesetzlichen Vorgaben unter spezieller Berücksichtigung der 12. AMG-Novelle ***
2004 Dr. Christine Binninger Regulatory standards on clinical trials for medical devices and medicinal products in case of orthopedically used hyaluronic acid
2004 Dr. Ingeborg Cebulla Changes to biological medicinal products (Case Study: Vaccines) ***
2004 Dr. Ulrike Domack Regulatory Science on Orphan Drug Application within Paediatric Field ***
  • Total: 720